Colorized scanning electron micrographs of natural killer cells from a human donor (Images: NIH / Graphics: Shehla Shakoor, Endpoints News)
November 12, 2019 03:22 PM ESTUpdated November 13, 10:23 AM
R&D

Kiadis aban­dons lead PhI­II pro­gram, shifts fo­cus to nat­ur­al killer cells

Jason Mast

Editor

Kiadis Phar­ma an­nounced that it is shift­ing fo­cus to nat­ur­al killer cells — and is it­self killing off the long-run­ning but deeply trou­bled Phase III ATIR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease med­i­cine: ‘We need to sit down with Elon Musk’

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves

Can Bill An­der­son save Bay­er?

Phar­ma-backed Mis­sion Ther­a­peu­tics stops pre­clin­i­cal op­er­a­tions, fo­cus­es on two clin­i­cal as­sets

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times